Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk

MacRae R.F. Linton, Sergio Fazio

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


It is now widely accepted that low-density lipoprotein (LDL) is not the only atherogenic component of the lipid profile and that abnormalities in the metabolism and plasma levels of triglycerides and high-density lipoprotein (HDL) may lead to accelerated growth of atherosclerotic lesions. Fibrates are the drugs of first choice in the management of hypertriglyceridemia, and are also able to substantially raise HDL. The recently published Veterans Administration-High-density Lipoprotein Intervention Trial (VA-HIT) trial showed that fibrate treatment in patients with coronary heart disease (CHD), low HDL, modestly elevated triglycerides, and normal LDL reduces the risk of a recurrent coronary event by 25%. A reasonable approach to the dyslipidemic patient with high CHD risk is to tailor the intervention to the specific lipoprotein abnormality. Under these assumptions fibrate therapy should become widespread, considering that the most common lipid alteration in CHD and patients with diabetes is low HDL and high triglycerides.

Original languageEnglish (US)
Pages (from-to)29-35
Number of pages7
JournalCurrent atherosclerosis reports
Issue number1
StatePublished - Dec 2000
Externally publishedYes


  • Coronary Heart Disease Risk
  • Fenofibrate
  • Gemfibrozil
  • Lovastatin
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk'. Together they form a unique fingerprint.

Cite this